Considering that certain cancers don't readily respond to HDAC inhibition and that some malignancies that initially respond to these treatments will develop resistance [23], it is essential to determine the factors that contribute to chemosensitivity and those which prevent chemotherapeutics from exerting their cytotoxic effects. This evidence concerns the gene HDAC9 and cancer.